Sleep disorders in myotonic dystrophy type 1 (DM1) are common and include sleep-disordered breathing, hypersomnia, and fatigue. Little is known regarding the occurrence of sleep disturbance in myotonic dystrophy type 2 (DM2). We hypothesized that DM2 patients may frequently harbor sleep disorders. We reviewed medical records of all genetically confirmed cases of DM2 seen at our sleep center between 1997 and 2010 for demographic, laboratory, overnight oximetry, and polysomnography (PSG) data. Eight patients (5 women, 3 men) with DM2 were identified. Excessive daytime sleepiness was seen in 6 patients (75%), insomnia in 5 (62.5%), and excessive fatigue in 4 (50%). Obstructive sleep apnea was diagnosed in 3 of 5 patients (60%) studied with PSG. Respiratory muscle weakness was present in all 6 patients (100%) who received pulmonary function testing. Four of 8 (50%) met criteria for diagnosis of restless legs syndrome. The clinical spectrum of DM2 may include a wide range of sleep disturbances. Although respiratory muscle weakness was frequent, sustained sleep-related hypoxia suggestive of hypoventilation was not seen in our patients. Further prospective studies are needed to examine the frequency and scope of sleep disturbances in DM2.

Keywords:
Myotonic dystrophy type 2, DM2, Excessive daytime sleepiness, EDS, Fatigue, OSA, RLS
1.
Turner C, Hilton-Jones D: The myotonic dystrophies: diagnosis and management. J Neurol Neurosurg Psychiatry 2010;81:358–367.
2.
Day JW, Ricker K, Jacobsen JF, et al: Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum. Neurology 2003;60:657–664.
3.
Meola G: Clinical and genetic heterogeneity in myotonic dystrophies. Muscle Nerve 2000;23:1789–1799.
4.
Liquori CL, Ricker K, Moseley ML, et al: Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 2001;293:864–867.
5.
Ricker K, Koch MC, Lehmann-Horn F, et al: Proximal myotonic myopathy: a new dominant disorder with myotonia, muscle weakness, and cataracts. Neurology 1994;44:1448–1452.
6.
Phemister JC, Small JM: Hypersomnia in dystrophia myotonica. J Neurol Neurosurg Psychiatry 1961;24:173–175.
7.
Laberge L, Bégin P, Montplaisir J, et al: Sleep complaints in patients with myotonic dystrophy. J Sleep Res 2004;13:95–100.
8.
Laberge L, Bégin P, Dauvilliers Y, et al: A polysomnographic study of daytime sleepiness in myotonic dystrophy type 1. J Neurol Neurosurg Psychiatry 2009;80:642–646.
9.
Phillips MF, Steer HM, Soldan JR, et al: Daytime somnolence in myotonic dystrophy. J Neurol 1999;246:275–282.
10.
Romigi A, Izzi F, Pisani V, et al: Sleep disorders in adult-onset myotonic dystrophy type 1: a controlled polysomnographic study. Eur J Neurol 2011;18:1139–1145.
11.
Ono S, Kurisaki H, Sakuma A, Nagao K: Myotonic dystrophy with alveolar hypoventilation and hypersomnia: a clinicopathological study. J Neurol Sci 1995;128:225–231.
12.
Yu H, Laberge L, Jaussent I, et al: Daytime sleepiness and REM sleep characteristics in myotonic dystrophy: a case-control study. Sleep 2011;34:165–170.
13.
Tieleman AA, Knoop H, van de Logt AE, et al: Poor sleep quality and fatigue but no excessive daytime sleepiness in myotonic dystrophy type 2. J Neurol Neurosurg Psychiatry 2010;81:963–967.
14.
Iber C, Ancoli-Israel S, Chesson A, et al: The AASM manual for scoring of sleep and associated events. Rules, terminology and technical specifications. Westchester, IL: American Academy of Sleep Medicine 2007 pp 45–47.
15.
Johns MW: A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 1991;14:540–545.
16.
Laberge L, Gagnon C, Jean S, et al: Fatigue and daytime sleepiness rating scales in myotonic dystrophy: a study of reliability. J Neurol Neurosurg Psychiatry 2005;76:1403–1405.
17.
Auvinen S, Suominen T, Hannonen P, et al: Myotonic dystrophy type 2 found in two of sixty-three persons diagnosed as having fibromyalgia. Arthritis Rheum 2008;58:3627–3631.
18.
Viola-Saltzmann M, Watson NF, Bogart A, et al: High prevalence of restless legs syndrome among patients with fibromyalgia: a controlled cross-sectional study. J Clin Sleep Med 2010;15:423–427.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.